Story thread · 8 reports / 6 sources
Tyra disappoints investors with bladder cancer data
biopharmadive.com · 5d
How the coverage leans
Across 6 sources · syndicated copies counted once
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
First report: Tyra claims Phase 2 win in bladder cancer, will advance drug to pivotal trial — endpts.com, 5d
The coverage
- Rezolute says late-stage trial data for lead asset remains under FDA review
seekingalpha.com · 5d
- Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
investors.com · 5d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.